Seok Jungirl, Ryu Chang Hwan, Ryu Junsun, Kim Ji-Hyun, Lee Sang-Jin, Park Weon Seo, Jung Yuh-Seog
Department of Otorhinolaryngology-Head and Neck Surgery, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si 10408, Gyeonggi-do, Korea.
Division of Cancer Immunology, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si 10408, Gyeonggi-do, Korea.
Biology (Basel). 2020 Nov 9;9(11):387. doi: 10.3390/biology9110387.
For oropharyngeal squamous cell carcinoma (OPSCC), there are not enough additional robust biomarkers for subgrouping after the distinct classification using p16. As SOX2 is an emerging biomarker for cancer treatment, its clinical implication in OPSCC was evaluated using a consecutive tissue microarray (TMA) cohort consisting of 111 patients who underwent surgery as an initial treatment from May 2002 to December 2016 and 79 patients in The Cancer Genome Atlas (TCGA) dataset. In both datasets, p16+ (HPV+/ in TCGA) showed the best prognosis among the four groups classified by SOX2 and p16 for 5-year overall survival (OS) and recurrence (all < 0.05), but SOX2 did not make a significant difference in the prognosis of the p16- group. In the TMA cohort, SOX2 was significantly correlated with response to radiotherapy and lower pathologic T classification in the p16+ group ( = 0.001). In TCGA, correlations between and tumor stage classification or radiotherapy were not observed; however, HPV+/ had a significantly low tumor mutation burden among the four groups (all < 0.05). In summary, SOX2 was proven to be a potential marker to predict overall survival and recurrence in p16+ OPSCC. However, the role of SOX2 has not yet been confirmed in p16- OPSCC patients.
对于口咽鳞状细胞癌（OPSCC），在使用p16进行明确分类后，没有足够的其他可靠生物标志物用于亚组划分。由于SOX2是一种新兴的癌症治疗生物标志物，因此使用一个连续组织微阵列（TMA）队列对其在OPSCC中的临床意义进行了评估，该队列包括2002年5月至2016年12月期间接受手术作为初始治疗的111例患者以及癌症基因组图谱（TCGA）数据集中的79例患者。在这两个数据集中，对于5年总生存期（OS）和复发情况，p16 +（在TCGA中为HPV + /）在按SOX2和p16分类的四组中显示出最佳预后（所有P <0.05），但SOX2在p16 -组的预后中没有显著差异。在TMA队列中，SOX2与p16 +组中对放疗的反应和较低的病理T分级显著相关（P = 0.001）。在TCGA中，未观察到SOX2与肿瘤分期分类或放疗之间的相关性；然而，HPV + /在四组中具有显著较低的肿瘤突变负担（所有P <0.05）。总之，SOX2被证明是预测p16 + OPSCC总生存期和复发的潜在标志物。然而，SOX2在p16 - OPSCC患者中的作用尚未得到证实。
